Drug Update: May 2017

New Drug Approvals

FDA Approves New Drug for Rare, Progressive Nerve Disease

Earlier this month, the U.S. Food & Drug Administration (FDA) approved a new medication, Radicava® (edaravone), for the treatment of patients with amytrophic lateral sclerosis (ALS), also known as Lou Gehrig’s disease. ALS is a rare progressive disease affecting nerve cells used for voluntary movement. The condition leads to muscle weakness as well as paralysis and respiratory failure. It is estimated approximately 15,000 individuals in the U.S. have ALS. Radicava is the first new treatment approved for ALS in more than 20 years and was granted orphan drug designation by the FDA for this use. Read more